Announcements Trials
Browse Landscape

Phase

Phase EARLY_PHASE1 1Phase 1/2 1

Status

Recruiting 1Enrolling by invitation 1

Sponsor Class

OTHER 1INDUSTRY 1

Study Type

Interventional 2

Sponsor

Cancer Type

Gastrointestinal 2CNS 2Other hematologic neoplasm 1Genitourinary 1Classical hematology 1

Conditions

Brain Neoplasms 643Glioblastoma 575Glioma 412Neuroblastoma 174Neoplasms 125Astrocytoma 108Central Nervous System Neoplasms 105Medulloblastoma 89Breast Neoplasms 86Meningioma 85Carcinoma, Non-Small-Cell Lung 79Melanoma 77Lung Neoplasms 70Sarcoma 66Ependymoma 65Neurofibromatosis 1 63Recurrence 50Oligodendroglioma 48Neoplasm Metastasis 48Osteosarcoma 47Meningeal Carcinomatosis 47Diffuse Intrinsic Pontine Glioma 46Rhabdomyosarcoma 45Pheochromocytoma 44Paraganglioma 42Rhabdoid Tumor 41Gliosarcoma 40Sarcoma, Ewing 39Pancreatic Neoplasms 39Colorectal Neoplasms 33

Interventions

atezolizumab 1

Date Range

30 days90 days1 yearAll

Options

Has results Has announcements

Clinical Trials

2 trials
RecentStart dateEnrollment
Adenoviridae Infections × CNS × 1 year × Clear all
NCT07538128 2026-04-20

Evaluating Safety, Tolerability, and Preliminary Efficacy of YSCH-01 Monotherapy and in Combination With Atezolizumab for Recurrent Glioblastoma

Huashan Hospital

Phase EARLY_PHASE1 Recruiting
10 enrolled
CNS

Adenoviridae Infections, Glioblastoma

NCT06763965 2026-03-23

Evaluating the Safety and Efficacy of BioTTT001 in Patients With Recurrent/Progressive High-grade Glioma.

Beijing Bio-Targeting Therapeutics Technology Co., Ltd

Phase 1/2 Enrolling by invitation
30 enrolled
CNS

Adenoviridae Infections, Glioma

Data powered by HemOnc (CC BY 4.0) Colophon âš¡